News
HKMPF
26.56
NaN%
--
Weekly Report: what happened at HKMPF last week (0414-0418)?
Weekly Report · 6d ago
Hikma acquires rights to generic version of Novartis' Mekinist
Seeking Alpha · 04/17 18:22
Weekly Report: what happened at HKMPF last week (0407-0411)?
Weekly Report · 04/14 10:23
Weekly Report: what happened at HKMPF last week (0331-0404)?
Weekly Report · 04/07 10:22
Weekly Report: what happened at HKMPF last week (0324-0328)?
Weekly Report · 03/31 10:29
Weekly Report: what happened at HKMPF last week (0317-0321)?
Weekly Report · 03/24 10:22
Weekly Report: what happened at HKMPF last week (0310-0314)?
Weekly Report · 03/17 10:28
Weekly Report: what happened at HKMPF last week (0303-0307)?
Weekly Report · 03/10 10:30
Axsome resolves patent dispute with Hikma
Seeking Alpha · 03/05 13:07
Weekly Report: what happened at HKMPF last week (0224-0228)?
Weekly Report · 03/03 10:29
John Hancock Disciplined Value International Fund Q4 2024 Commentary
Seeking Alpha · 02/28 12:40
Hikma Pharmaceuticals reports FY results
Seeking Alpha · 02/26 09:36
Weekly Report: what happened at HKMPF last week (0217-0221)?
Weekly Report · 02/24 10:29
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Seeking Alpha · 02/20 04:59
Weekly Report: what happened at HKMPF last week (0210-0214)?
Weekly Report · 02/17 10:28
Weekly Report: what happened at HKMPF last week (0203-0207)?
Weekly Report · 02/10 10:24
Weekly Report: what happened at HKMPF last week (0127-0131)?
Weekly Report · 02/03 10:27
Weekly Report: what happened at HKMPF last week (0120-0124)?
Weekly Report · 01/27 10:29
Weekly Report: what happened at HKMPF last week (0113-0117)?
Weekly Report · 01/20 10:23
Weekly Report: what happened at HKMPF last week (0106-0110)?
Weekly Report · 01/13 10:24
More
Webull provides a variety of real-time HKMPF stock news. You can receive the latest news about Hikma Pharma through multiple platforms. This information may help you make smarter investment decisions.
About HKMPF
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). It is also engaged in the finished dosage form (FDF) business and has a manufacturing facility in Cleveland, Ohio. The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio.